10x Genomics, Inc. — Director's Dealing 2026

Mar 4, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2026-03-02

Reporting Person: Saxonov Serge (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-03-02	Class A Common Stock	S	14292	$22.669	Disposed	1205527	Direct
2026-03-02	Class A Common Stock	S	1860	$23.1781	Disposed	1203667	Direct
2026-03-03	Class A Common Stock	G	2750	—	Disposed	1200917	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	27	Indirect
Class A Common Stock	213250	Indirect
Class A Common Stock	58000	Indirect

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on November 29, 2025.

F2: This transaction was executed in multiple trades at prices ranging from $22.15 to $23.145, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $23.15 to $23.25, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.

F5: The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.

F6: The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.